ArticleUrology case reports2025
Cough-associated detrusor overactivity resolved after intravesical onabotulinumtoxin A injection: A case report.
Article in Urology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 68-year-old woman developed urgency urinary incontinence (UUI) one month after tension-free vaginal tape (TVT) surgery for stress urinary incontinence. Pharmacological treatment was ineffective. Pressure-flow study revealed cough-associated detrusor overactivity (CADO). An intravesical injection of 100 U botulinum toxin resolved symptoms and normalized bladder sensation. Six months later, CADO recurred and was successfully treated with a second injection. No adverse events occurred. CADO is often misdiagnosed as stress incontinence, and accurate diagnosis requires urodynamic evaluation. This case highlights the potential of intravesical botulinum toxin for managing CADO, including recurrence. Further studies should establish optimal diagnostic strategies and long-term efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.